Rapport Therapeutics, Inc. Research and Development Expense
Rapport Therapeutics, Inc. (RAPP) reported Research and Development Expense of $51.41 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- Rapport Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $51.41M, a 126.69% increase year-over-year.
- Rapport Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $32.72M, a 67.16% increase year-over-year.
- Rapport Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $30.26M, a 75.93% increase year-over-year.
- Rapport Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $22.28M, a 43.34% increase year-over-year.
- Rapport Therapeutics, Inc. research and development expense for fiscal 2025 was $94.79M, a 55.56% increase from fiscal 2024.
- Rapport Therapeutics, Inc. research and development expense for fiscal 2024 was $60.94M, a 117.63% increase from fiscal 2023.
- Rapport Therapeutics, Inc. research and development expense for fiscal 2023 was $28.00M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $51.41M 10-Q · filed 2026-08-05 | $84.13M 10-Q · filed 2026-08-05 | $114.39M derived: sum of 3 quarters · filed 2026-08-05 | $136.67M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $32.72M 10-Q · filed 2026-05-07 | $62.97M derived: sum of 2 quarters · filed 2026-05-07 | $85.25M derived: sum of 3 quarters · filed 2026-05-07 | $107.93M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $30.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $52.54M derived: sum of 2 quarters · filed 2026-03-10 | $75.22M derived: sum of 3 quarters · filed 2026-08-05 | $94.79M 10-K · filed 2026-03-10 |
| 2025-09-30 | $22.28M 10-Q · filed 2025-11-06 | $44.96M derived: sum of 2 quarters · filed 2026-08-05 | $64.53M 10-Q · filed 2025-11-06 | $81.73M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $22.68M 10-Q · filed 2026-08-05 | $42.25M 10-Q · filed 2026-08-05 | $59.45M derived: sum of 3 quarters · filed 2026-08-05 | $74.99M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $19.57M 10-Q · filed 2026-05-07 | $36.77M derived: sum of 2 quarters · filed 2026-05-07 | $52.31M derived: sum of 3 quarters · filed 2026-05-07 | $68.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $17.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $32.74M derived: sum of 2 quarters · filed 2026-03-10 | $48.43M derived: sum of 3 quarters · filed 2026-03-10 | $60.94M 10-K · filed 2026-03-10 |
| 2024-09-30 | $15.54M 10-Q · filed 2025-11-06 | $31.23M derived: sum of 2 quarters · filed 2025-11-06 | $43.74M 10-Q · filed 2025-11-06 | $55.53M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $15.69M 10-Q · filed 2025-08-07 | $28.19M 10-Q · filed 2025-08-07 | $39.99M derived: sum of 3 quarters · filed 2025-08-07 | $47.57M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $12.50M 10-Q · filed 2025-05-08 | $24.30M derived: sum of 2 quarters · filed 2025-05-08 | $31.88M derived: sum of 3 quarters · filed 2025-05-08 | $36.60M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $11.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $19.38M derived: sum of 2 quarters · filed 2025-03-11 | $24.10M derived: sum of 3 quarters · filed 2025-03-11 | $28.00M 10-K · filed 2025-03-11 |
| 2023-09-30 | $7.58M 10-Q · filed 2024-11-07 | $12.30M derived: sum of 2 quarters · filed 2024-11-07 | $16.20M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $4.72M 10-Q · filed 2024-08-08 | $8.62M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |